✦ LIBER ✦

Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease

✍ Scribed by Janssen, Robert S.; Mangoo-Karim, Roberto; Pergola, Pablo E.; Girndt, Matthias; Namini, Hamid; Rahman, Sophia; Bennett, Sean R.; Heyward, William L.; Martin, J. Tyler

Book ID: 123441576
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 961 KB
Volume: 31
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2013.05.067

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immunogenicity and safety of an investig

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age

✍ Heyward, William L.; Kyle, Michael; Blumenau, Joseph; Davis, Matthew; Reisinger, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 517 KB

Demonstration of safety and enhanced ser

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

✍ Benjamin P. Sablan; Dong Joon Kim; Nina G. Barzaga; Wan Cheng Chow; Mong Cho; Sa 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 396 KB

Safety and immunogenicity of hepatitis A

Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease

✍ Emmet B. Keeffe; Sten Iwarson; Brian J. McMahon; Karen L. Lindsay; Raymond S. Ko 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

Acute hepatitis A superimposed on chronic liver disease (CLD) has been associated with severe or fulminant hepatitis. An open, multicenter study was performed to compare the safety and immunogenicity of an inactivated hepatitis A vaccine in patients with CLD with that in healthy subjects. A secondar

Comparison of safety and immunogenicity

Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age

✍ Scott A. Halperin; Brian Ward; Curtis Cooper; Gerald Predy; Francisco Diaz-Mitom 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 344 KB

Efficacy of a Hepatitis B Vaccination Sc

Efficacy of a Hepatitis B Vaccination Schedule With Two Cycles of Four Double Doses of Conventional Vaccine and Four Doses of Adjuvanted Vaccine in Chronic Kidney Disease Patients Evaluated for Renal Transplantation

✍ García-Agudo, R.; Aoufi Rabih, S.; Araque Torres, P.; Dolores Fraga Fuentes, M.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 278 KB

Immunogenicity and safety of an investig

Immunogenicity and safety of an investigational AS02v-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: Results of two open, randomized, comparative trials

✍ Christian L. Tielemans; Jiri Vlasak; Dezider Kosa; Jean-Marie Billiouw; Gert A. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 249 KB